ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

SBTX Skinbiotherapeutics Plc

9.25
0.00 (0.00%)
31 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Skinbiotherapeutics Plc LSE:SBTX London Ordinary Share GB00BF33H870 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 9.25 9.00 9.50 9.50 9.25 9.25 122,323 10:38:51
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Biological Pds,ex Diagnstics 132k -2.84M -0.0163 -5.67 16.1M
Skinbiotherapeutics Plc is listed in the Biological Pds,ex Diagnstics sector of the London Stock Exchange with ticker SBTX. The last closing price for Skinbiotherapeutics was 9.25p. Over the last year, Skinbiotherapeutics shares have traded in a share price range of 7.25p to 29.50p.

Skinbiotherapeutics currently has 174,004,323 shares in issue. The market capitalisation of Skinbiotherapeutics is £16.10 million. Skinbiotherapeutics has a price to earnings ratio (PE ratio) of -5.67.

Skinbiotherapeutics Share Discussion Threads

Showing 3301 to 3323 of 23800 messages
Chat Pages: Latest  136  135  134  133  132  131  130  129  128  127  126  125  Older
DateSubjectAuthorDiscuss
08/4/2019
07:07
Dr Cath O'Neill, CEO of SkinBioTherapeutics, said:"We are really pleased by these data. To show efficacy at this stage of development is very exciting since there is a lot of scope for us to further optimise the formulation, potentially altering the dose of the SkinBiotix(R) to make it more suitable for different age groups.It is very difficult to change a healthy barrier and therefore the data showing improvement in some age groups gives us confidence in our partner discussions, and in seeking to develop future applications in disease conditions where the barrier is known to be poor such as eczema".
parob
08/4/2019
07:06
Not great results imho
f3rdinand
06/4/2019
08:16
Good skin results here over the next couple of weeks should give OPTI an extra boost and the timing couldn't be better as the share price breaks out.
parob
05/4/2019
17:19
Awful time to sell imo. All signs point to good news from results. Someone bottling it by looks of it.
riskybusiness1
05/4/2019
16:17
There it is the 125K share sale that has been holding us back today.
rafboy
05/4/2019
15:59
Should easily break through by next week. Results should be out next week/week after. If they're good this will see reach new highs
riskybusiness1
05/4/2019
15:12
20 resistance can't be that strong. Its blasted past it 2 times out 3 and both hit 29p.
slartybartfaster
05/4/2019
13:17
20p has strong resistance. Once it breaks after a few more buys should move up to mid 20s pretty swiftly I would hope.
riskybusiness1
05/4/2019
12:44
IMO, the share price should be around 21-22p today but I think there is a 100k plus seller still around.
gostaa
05/4/2019
12:28
Yes must be as if all these buys were sales we would be 5% down by now
onedayrodders
05/4/2019
11:49
There must be another 100k background sell given the stagnant share price today after what appears to be a lot of buys.
gostaa
05/4/2019
11:32
Must be due a tick up after all the buys this morning.
rafboy
04/4/2019
08:36
Stand back ... she's alive at long last :o)
onedayrodders
03/4/2019
15:20
Not really. It allowed me to add at almost half the price i was willing to pay.
slartybartfaster
03/4/2019
12:56
looking good ..shame we lost that momentum in mid Feb and had to start again
onedayrodders
03/4/2019
11:51
Who said I don’t have shares? If the tech works then there’ll be a bun fight to get exclusivity. Could well end in TO, hopefully a share buyout 🤪
pretax2
03/4/2019
10:09
Good to see the buyers this morning, not long to wait.
rafboy
02/4/2019
19:51
Pretax2 it must be very reassuring to yourself that you don’t own any shares then. I can’t see this company being sold out any time soon. All I can see is a big jump up in share price within the next few weeks.
jamesrs1
02/4/2019
17:35
If it’s nailed on that’s probably the reason the share price is where it is. This company is just simply waiting for takeover
pretax2
02/4/2019
16:29
It's pretty obvious there isn't any issues. All major milestone were past quite quickly. The last possible stumbling block was increased dose to test irritancy if there was a need to increase the dose. This also passed. We also know nobody has left the trials which is another plus. Nailed on success imo.
slartybartfaster
01/4/2019
21:06
We already know it’s safe it’s all about increasing the moisture levels of the skin the greater the levels the better.
best1467
01/4/2019
13:04
Stuart Ashman looks like a top signing to drive this forward, clearly has massive contacts in this space. His expertise is commercialising product....He wouldn't of come aboard if the science wasn't progressing well enough to do so. Big hint the first 60 subjects results were good.As the study is cosmetic & they are testing healthy skin the primary objectives will not be as simple to analyse its impact as say cholesterol reduction like LPLDL with Opti. The biggest thing will be it's safety & some indication of the its impact on skin health. This is different from say testing subjects with eczema and testing whether it works or not.
riskybusiness1
01/4/2019
12:30
She only answered a direct question from me as most of us assume it's the be all and end all as it clearly isn't
onedayrodders
Chat Pages: Latest  136  135  134  133  132  131  130  129  128  127  126  125  Older